-
公开(公告)号：US20240115721A1
公开(公告)日：2024-04-11
申请号：US18272050
申请日：2022-01-13
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE , DAIICHI SANKYO COMPANY, LIMITED
发明人： John T. POIRIER , Charles RUDIN , Jason LEWIS , Abdul KHAN , David ANDREW , Xinlei CHEN , Ivo LORENZ , Hironori MATSUNAGA
CPC分类号： A61K47/68037 , A61K47/6851 , A61P35/00 , C07K16/28
摘要： It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
-
公开(公告)号：US20240115720A1
公开(公告)日：2024-04-11
申请号：US18272049
申请日：2022-01-13
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE , DAIICHI SANKYO COMPANY, LIMITED
发明人： John T. POIRIER , Charles RUDIN , Jason LEWIS , Abdul KHAN , David ANDREW , Xinlei CHEN , Ivo LORENZ , Hironori MATSUNAGA
IPC分类号： A61K47/68 , A61K31/5517 , A61P35/00 , C07K16/28
CPC分类号： A61K47/68035 , A61K31/5517 , A61K47/6849 , A61P35/00 , C07K16/28 , A61K2039/505
摘要： The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.
-
公开(公告)号：US20220348648A1
公开(公告)日：2022-11-03
申请号：US17622404
申请日：2020-07-08
发明人： John T. POIRIER , Charles RUDIN , Jason LEWIS , Abdul KHAN , David ANDREW , Xinlei CHEN , Ivo LORENZ
摘要： The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.
-
公开(公告)号：US20230391890A1
公开(公告)日：2023-12-07
申请号：US18249187
申请日：2021-10-15
发明人： David C. LYDEN , Goncalo RODRIGUES , Irena RAJNPREHT , Abdul KHAN , Ivo LORENZ , Irina MATEI
CPC分类号： C07K16/40 , A61P35/04 , C07K2317/76 , C07K2317/92
摘要： The present disclosure relates to antibody-based molecules, including antibodies, epitope-binding domains thereof, and antibody derivative as described herein, that are capable of binding and inhibiting cell migration-inducing and hyaluronan-binding protein (CEMIP). Such antibody-based molecules are useful for the treatment of conditions where a subject is in need of blocking the activity of CEMIP.
-
公开(公告)号：US20230190797A1
公开(公告)日：2023-06-22
申请号：US16627272
申请日：2018-07-02
IPC分类号： A61K35/17 , C12N9/48 , C07K14/705 , C07K14/725 , C07K16/28 , C07H19/16 , C07K16/30 , C12N9/86 , A61P31/12 , A61P31/04 , A61P29/00 , A61K45/06
CPC分类号： A61K35/17 , C12N9/485 , C07K14/70517 , C07K14/7051 , C07K16/2803 , C07K14/70578 , C07H19/16 , C07K16/3038 , C07K16/3053 , C12Y304/17011 , C12N9/86 , C12Y305/02006 , A61P31/12 , A61P31/04 , A61P29/00 , A61K45/06 , C07K2319/03 , C07K2317/622 , C07K2319/02
摘要： Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.
-
公开(公告)号：US20200157518A1
公开(公告)日：2020-05-21
申请号：US16627267
申请日：2018-07-02
IPC分类号： C12N9/48 , C07K16/28 , A61K9/00 , C12N5/0783 , A61K45/06 , C07K14/52 , A61K35/17 , A61P35/00 , C07D519/00 , C07D501/16 , C07D239/94
摘要： Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.028 秒)
